Dr. Dominik Escher is a founding managing partner of Pureos Bioventures. He is also a co-founder and Executive Chairman of CDR-Life and President of the Swiss Biotech Association. Previously, he was a founder and CEO of ESBATech, which was acquired by Alcon (Novartis) for USD 589 million in 2009. Subsequent to the acquisition, Dominik was VP of R&D at Alcon and a member of the Group’s Global R&D Leadership Team and, on acquisition of Alcon by Novartis, a member of the Novartis Institutes of Biomedical Research (NIBR) Global Ophthalmology Leadership Team.
As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to clinical proof-of-concept, delivering multiple clinically successful products (e.g. Beovu). Dominik obtained his Ph.D. in Molecular Biology from the University of Zurich and also holds a Masters Degree in Education with specialization in Management and Organization from the ETH of Zurich.